Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.
LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...
A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment. Initial diagnosis and treatment left the author feeling weak and ...
News Medical on MSN
New trial tests strategies to protect heart health during prostate cancer therapy
City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by ...
The FINANCIAL — Abbott Park, Illinois — Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot® ...
Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...
Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care. Following the 2025 European Society of Medical Oncology (ESMO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results